TAK Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TAK) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 19% planned / 81% discretionary
Largest single sale: $2.8M.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Duprey Lauren Rusckowski | Chief Transformation Officer | Sell | 34,535 | $18.54 | $640.3K | 191,522 −15.3% of holding | |
| Plump Andrew Stewart | President, R&D | Sell 10b5-1 | 116,191 | $18.49 | $2.1M | 145,465 −44.4% of holding | |
| Plump Andrew Stewart | President, R&D | Sell 10b5-1 | 19,651 | $18.49 | $363.3K | 261,656 −7% of holding | |
| Greenway Nicola Deidre Petal | Chief Human Resources Officer | Sell | 12,980 | $18.11 | $235.1K | 40,049 −24.5% of holding | |
| Shannon Elaine Mary | Pres., Global Supply & Quality | Sell | 20,363 | $17.55 | $357.4K | 67,311 −23.2% of holding | |
| Plump Andrew Stewart | President, R&D | Sell | 165,393 | $17.10 | $2.8M | 766,569 −17.7% of holding | |
| Kim Julie So-Young | President and CEO | Sell | 89,090 | $17.10 | $1.5M | 391,489 −18.5% of holding | |
| Bitetti Teresa Marie | President, OBU | Sell | 50,012 | $17.10 | $855.2K | 252,010 −16.6% of holding | |
| Duprey Lauren Rusckowski | Chief Transformation Officer | Sell | 47,586 | $17.10 | $813.7K | 226,057 −17.4% of holding | |
| Greenway Nicola Deidre Petal 3 fills | Chief Human Resources Officer | Sell | 41,377 | $17.44 | $721.6K | 93,431 −30.7% of holding | |
| Platford Giles Richard | President, IBU | Sell | 31,083 | $17.10 | $531.5K | 315,838 −9% of holding | |
| Furney Natalie Anne Marie | Global General Counsel | Sell | 30,868 | $17.10 | $527.8K | 204,298 −13.1% of holding | |
| Ricci Gabriele | Chief Data & Tech. Officer | Sell | 25,088 | $17.10 | $429.0K | 171,654 −12.8% of holding | |
| Pignagnoli Agosti Marcello | Head, Strat. & Port. Dev | Sell | 22,957 | $17.10 | $392.6K | 176,977 −11.5% of holding | |
| Pacheco Rhonda Janice | President, U.S. Business Unit | Sell | 16,901 | $17.10 | $289.0K | 182,507 −8.5% of holding | |
| Farajallah Awny Samaan Botros | Chief Medical Officer | Sell | 14,006 | $17.10 | $239.5K | 116,177 −10.8% of holding | |
| Ibrahim Ramy Riad Ahmed | President, PDT BU | Sell | 7,277 | $17.10 | $124.4K | 102,588 −6.6% of holding | |
| Shannon Elaine Mary | Pres., Global Supply & Quality | Sell | 3,978 | $17.10 | $68.0K | 63,333 −5.9% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.